Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

CMR Molecular Imaging highlights American Journal of Roentgenology (AJR) article on Molecular Breast Imaging (MBI)


Researchers have found that Molecular Breast Imaging (MBI) provides an Incremental Cancer Detection Rate (ICDR) over mammography per 1000 woman with dense breast screened. Rhodes et al. AJR 2015

Published in the AJR August 2020 edition, the purpose of this article is to review clinical uses and image interpretation of molecular breast imaging (MBI) and clarify radiation risks.

Authors Elizabeth H. Dibble, Department of Diagnostic Imaging, The Warren Alpert Medical School of Brown University, and Katie N. Hunt, Eric C. Ehman, Michael K. O’Connor, Department of Radiology, Mayo Clinic, concluded that MBI detects additional cancers compared with conventional imaging in women with dense breasts and those with elevated risk of breast cancer. Its role as an imaging biomarker of cancer risk and in assessing neoadjuvant chemotherapy response is growing. Radiation risk is minimal; benefit-to-risk ratio is similar to that of mammography. MBI is low cost, well tolerated, and easily adapted into clinical practice.

Read More: https://www.ajronline.org/doi/abs/10.2214/AJR.19.22622

CMR Molecular Imaging manufactures and commercializes the LumaGEM ® MBI system, with dual-head digital direct conversion gamma imaging, that provides high resolution images with less than 2 mm resolution, using a low dose of Tc99 Sestamibi radiotracer. With over 90 percent sensitivity and specificity, LumaGEM MBI® has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound.

Researchers have found and published data demonstrating that in women with dense breast tissue, MBI detects an additional 8.8 cancers per 1000 women screened providing an incremental cancer detection rate (ICDR) of 250% over mammography. Rhodes et al. AJR 2015

About CMR Molecular Imaging: CMR Molecular Imaging is a unit of CMR Naviscan Corporation, a leader in organ-specific molecular imaging and part of the Compañia Mexicana de Radiologia CGR, S.A. de C.V. (CMR), a global developer and manufacturer of high quality diagnostic imaging equipment and healthcare information systems, including DICOM-compliant imaging software. CMR Naviscan, headquartered in Carlsbad, California, develops and manufactures molecular imaging systems, including the Solo II™ High Resolution Breast PET Imaging (BPI) scanner, the Stereo Navigator® Biopsy Guidance Accessory, and the LumaGEM® Molecular Breast Imaging (MBI) system. CMR Naviscan is US FDA registered and ISO 13485:2012 certified.

For more information visit http://www.cmr-naviscan.com

Share article on social media or email:

Paubox SECURE @ Home Brings 3rd Annual Virtual Healthcare and Cybersecurity Conference


News Image

“We are excited to move this conference online for 2020,” said Hoala Greevy, Founder CEO of Paubox. “Being virtual allows us to have experienced and dynamic speakers from around the country and helps us reach much more healthcare and IT professionals than a physical conference would.”

For its 3rd annual event, Paubox will present Paubox SECURE @ Home, taking place virtually on October 21 – 22, 2020, featuring keynote speakers like Jeremiah Grossman, CEO & Founder of Bit Discovery, and Kelvin Coleman, Executive Director of National Cyber Security Alliance.

Paubox SECURE @ Home is a healthcare cybersecurity and innovation conference. Focused on generating relevant content, discussions, and networking opportunities, this virtual conference is centered around the challenges of driving innovation in healthcare while keeping data safe.

Paubox SECURE @ Home is perfect for anyone who works in and around healthcare – from hospitals to payers, consultants to investors, and everyone in between. If you understand the rising threat of healthcare attacks, this conference will bring together industry leaders and professionals to network, learn, ask questions, and have meaningful discussions.

“We are excited to move this conference online for 2020,” said Hoala Greevy, Founder CEO of Paubox. “Being virtual allows us to have experienced and dynamic speakers from around the country and helps us reach much more healthcare and IT professionals than a physical conference would.”

Additional Keynote speakers will include Paddy Padmanabhan, CEO of Damo Consulting, Bruce Snell, Global VP Security Strategy & Transformation at NTT Security, Kurt Hagerman, Principal Cloud Security Advisor at Oracle, Rose-Marie Nsahlai, Senior Technical Advisor at ONC, James Plouffe, Sr. Partner Solutions Architect at AttackIQ, and Hector Rodriguez, Healthcare Industry Executive Director at Oracle.

For a complete list of speakers and ticketing information, visit pauboxsecure.com.

Paubox provides secure email communication for modern healthcare. Right out of the box. Paubox is a leading provider of HIPAA compliant email encryption and email marketing. Ranked number 1 Email Encryption Software according to G2 and ranked number 320 on the 2020 Inc. 500 list.

Share article on social media or email:

NeoTract Designates Dr. Peter Slocum as UroLift® Center of Excellence


News Image

“This designation recognizes Dr. Peter Slocum as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Peter Slocum, M.D., Madison Medical Affiliates in Milwaukee, WI, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Slocum has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Peter Slocum as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Buchanan & Edwards Completes Critical CGFS Initiative


This effort is a testament to BE’s commitment and partnership with CGFS and the Department of State.

Buchanan & Edwards Inc., an award-winning and fast-growing technology leader delivering transformative solutions for the national security community has successfully delivered a high-visibility and complex public website for the Bureau of the Comptroller and Global Financial Services (CGFS) for the U.S. Department of State’s Account Receivable Branch (ARB).

Buchanan & Edwards (BE) completed a high priority initiative with CGFS for the comprehensive development and launch of ARB’s public facing website, which is a resource for U.S. citizens and residents who received government-assisted global evacuations due to COVID-19. The unprecedented circumstances and large number of COVID-19 evacuees created an urgent demand for a widely accessible informational portal for the government’s evacuation loan recipients. BE started immediately – standing up the ARB site, distributing standard forms, publishing billing timelines, and providing frequently asked questions. By deploying these capabilities in an extremely compressed timeframe, BE was able to provide a valuable resource for pandemic evacuees.

“This effort is a testament to BE’s commitment and partnership with CGFS and the Department of State. Our team understood the critical nature of this complex project and went above and beyond to meet the compressed timeline and exceed the customers’ expectations,” said Eric Olson, CEO of Buchanan & Edwards. “I have seen multiple messages from CGFS leadership, including the Acting Comptroller, recognizing this massive effort, and we’re proud to have been part of this important initiative,” commented Olson.

“The global onset of the pandemic necessitated the immediate evacuation of our U.S. citizens and residents. Once citizens were repatriated, the need for a timely solution to assist our citizens and streamline resources for their evacuation repayments was very clear,” said Lionel Fleshman, CGFS Project Manager for Buchanan & Edwards. “Our team quickly organized and began driving this critical project, recognizing the multiple requirements, addressing hurdles, and ultimately delivering a solution in a very short timeframe. The dedication to this effort was undeniable and very much appreciated,” commented Fleshman.

To learn more about payment Information for government assisted evacuations due to COVID-19, visit the U.S. Department of State’s ARB’s website: https://cgfsaccountsreceivablebranch.state.gov/.

About Buchanan & Edwards

Since 1998, Buchanan & Edwards Inc. has served as a trusted partner on missions of vital importance to our customers, the nation and the world. In 2017, we acquired The Reports & Requirements Company (R2C), increasing our support to the nation’s most critical national security missions. Our experience in the defense, intelligence, law enforcement, and civilian markets combined with our expertise in data analytics & governance, cyber intelligence, operations support, cloud migration and digital services enable us to anticipate change and deliver tomorrow’s solutions today. For additional information, please visit our website at http://www.Buchanan-Edwards.com or follow us on Twitter, Facebook and LinkedIn.

Share article on social media or email:

Visikol and Melior Discovery Partner on Precision Cut Liver Ex Vivo NASH Models


Prior to partnering with Melior, Visikol had a robust portfolio of ex vivo human precision cut liver slice models (both healthy F0-F1 and diseased F3-F4) as well as in vitro 3D cell culture models which could all be used to evaluate the efficacy of its Client’s compounds in ameliorating NASH. In one iteration of such models, Visikol can stimulate disease progression in healthy 3D cell culture models or PCLS using TGF-β and/or PDGF-ββ or through a free fatty acid stimulation protocol. While these approaches tend to be slightly higher throughput due to normal tissue availability, to better evaluate efficacy in a disease model that presents the native disease architecture, Visikol can leverage F3 and F4 human PCLS to evaluate NASH amelioration.

The aim of partnering with Melior has been to further expand this suite of NASH models and to provide Clients with an even more diverse model offering. Through a partnership with Melior, Visikol will now be able to provide its Clients with a mouse CCl4 PCLS model of liver fibrosis, wherein liver fibrosis is chemically stimulated in vivo via a carbon tetrachloride injury model. This treatment scheme tends to cause hepatocyte damage, necrosis, inflammation and fibrosis after 14 days of challenge in a manner similar to that seen in normal human fibrotic disease progression.

“Since our Clients have targets that are relevant at various stages of NASH disease progression and are looking to evaluate compounds at different stages in the drug discovery pipeline, we find that it is best to provide them with a range of means for assessing their compounds,” described Visikol Head of Services Dr. Erin Edwards. “We’re excited to be able to offer this murine model, as it will go a long way towards helping our Clients achieve their study goals while using a highly reproducible model that is slightly higher throughput than human models, and aligns with 3R principles.”

In comparison to human based PCLS models, this CCl4 mouse model-based approach is highly reproducible, since subjects are from a genetically identical mouse strain and the disease state is induced in a repeatable, laboratory-staged protocol. Additionally, this approach allows for the use of genetically modified models and reduces the overall number of animals required in later stage studies as a single animal is being used to generate multiple PCLS models for analysis. Lastly, this offering enables Clients to conduct comparisons of efficacy between species, facilitating bridging of other preclinical studies.

If you are interested in discussing your NASH program in more detail and learning about the advantages and disadvantages of our different models, please reach out to Visikol today.

About Visikol Incorporated

Visikol is a CRO that is focused on accelerating drug discovery and development through the use of its imaging, digital pathology and advanced cell culture assay services. The company provides end-to-end preclinical services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, multiplex imaging, high content imaging, digital pathology and custom drug discovery solutions. Visikol’s expertise is in transforming tissues and cells into large image-based data sets that can be mined for actionable insights such that pharmaceutical and biotech companies can make more quantitative and informed decision during the drug development process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit http://www.visikol.com.

Share article on social media or email:

Accurate Covid-19 Serological Surveillance Using Easy-to-Collect Saliva Samples


Salimetrics Logo

…saliva sampling makes it possible to frequently and easily collect and test samples from the same person to unlock the much-needed data that can be used to map the magnitude and longevity of the immune response.

A new serological assay is poised to enhance COVID-19 surveillance efforts with a simple, easy-to-collect saliva sample. “Today, Salimetrics is pleased to announce that after rigorous evaluation and validation, the Salimetrics SalivaLab will offer SARS-CoV-2 N-Protein IgG testing services to researchers for use with oral fluid samples,” says Steve Granger, Ph.D. Salimetrics Chief Scientific Officer. “The Salimetrics SARS-CoV-2 assay is being offered as a “Research Use Only (RUO)” service, providing a better method to advance our understanding of disparities in COVID-19 exposure history, risk, morbidity, and mortality.”

This new offering employs a small test volume that can be processed in conjunction with saliva samples collected for active infection diagnosis. “Data has shown that results from saliva enriched with IgG (i.e., gingival crevicular fluid, and oral mucosal transudate) match COVID-19 IgG levels measured in serum exceptionally well. These findings by Randad et al (2020) reveal the utility of oral fluid for SARS-CoV-2 antibody detection. But the potential of saliva goes further. When the duration of the immune system’s response to infection is unknown, saliva sampling makes it possible to frequently and easily collect and test samples from the same person to unlock the much-needed data that can be used to map the magnitude and longevity of the immune response. In addition, the Salimetrics SalivaLab can also process serum samples, and when tested with matched saliva samples, the combined serological data is robust and well supported by validated controls. “We realize that accessibility to trustworthy, reliable data is key in supporting this effort,” says Granger, “so it’s important that Salimetrics is available and willing to provide answers that researchers need.”

For more than 20 years, Salimetrics has championed oral fluid sampling as an alternative to traditionally invasive specimens. Since oral fluid is minimally invasive, it can be safely and frequently self-collected. These implicit advantages of oral fluid as a biospecimen make it an ideal sample in the context of the COVID-19 pandemic. Now, broad population-based seroprevalence studies of recent and past infections can begin to answer how COVID-19 hotspots spread, which individual characteristics or risk factors contribute to SARS-CoV-2 infection severity, the ratio of asymptomatic vs. symptomatic cases, and how long COVID-19 antibodies remain in circulation.

While serological assays are generally serum-based, the current model was never designed to be implemented on a massive scale. Saliva provides this opportunity. With saliva, the ideal specimen is an enriched sample collected using the SalivaBio Saliva Collection Aid – OMT (SCA-OMT), exclusively from Salimetrics. The SCA-OMT consistently provides saliva samples that have been enriched above a Total IgG level threshold. For large seroprevalence surveys, whole saliva can also be collected efficiently and effectively using the Passive Drool Collection System with the SalivaBio Saliva Collection Aid, provided an additional qualification of Total IgG level is utilized for the negative samples.

Salimetrics stands by the research community to continue to drive research forward. “We are here to help. Use our experts to refine and optimize your sample collection, handling, storage, and transportation protocols for better results,” says Supriya Gaitonde, Ph.D., Salimetrics Senior Applications Scientist. “Together we can make a difference and find the answers.”

About Salimetrics:

Salimetrics assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health and immune function. Founded in 1998 by Douglas A. Granger, Ph.D., Salimetrics, LLC supports CROs, pharmaceuticals, academic researchers and the immunodiagnostic industry around the world with innovative immunoassay products, non-invasive saliva collection methods, and laboratory testing services.

Share article on social media or email:

Doctors Launch Online Course to Fight Chronic Inflammation and Disease


We want to teach people how to stay healthy and how to save healthcare dollars and avoid being wiped out.

Tame Your Flame, LLC, founded by chiropractors Dr. Louis Scoma and Dr. Eric Gerken, has launched an online e-learning platform at http://www.tamingyourflame.com to coach people on combating chronic inflammation, a leading cause of chronic diseases. 75 percent of the $3.5 trillion of healthcare dollars spent in the United States is for battling chronic disease according to the Centers for Disease Control and Prevention. This economic burden is the inspiration behind Taming your Flame.

“A recent study revealed that 66.5 percent of all bankruptcies were tied to medical issues. We want to teach people how to stay healthy and how to save healthcare dollars and avoid being wiped out,” said Dr. Scoma, president of Tame Your Flame and owner of Scoma Chiropractic.

Taming Your Flame is a series of five lessons that are self-paced. The program includes a self assessment tool to determine a personal baseline, in advance of the taking the five courses, establish a plan and re-assess in the future. Upon completion of the on-line lessons, students will understand the tools and tactics for mitigating chronic inflammation. A certificate of completion will be issued upon successful completion of the online classes signed by both doctors. A free course introduction is available on the Taming Your Flame YouTube channel.

The course outlines the progression of chronic disease from chronic inflammation to its culmination in named diagnoses such as Alzheimer’s, diabetes, obesity, heart, thyroid, and auto-immune disease. This chronic inflammation usually starts with dietary food allergies or sensitivities and stress, in combination with toxins, both internal and external. It always involves the gastrointestinal (GI) tract and imbalances between the external and internal environment, or the Microbiome.

“Chronic inflammation is at the intersection and is the common denominator of all auto-immune and other chronic diseases,” said Dr. Gerken, a functional medicine practitioner and diplomat of the American Board of Anti-Aging Medicine (A4M).

Subscribers to Taming Your Flame will also gain access to affiliates of Dr. Scoma and Dr. Gerken who share a like-minded philosophy toward diet and skincare. Affiliates offer pasture raised, truly free ranging, grass fed and grass finished meats and other non-GMO, organic or keto friendly products, free of paraben chemicals and glyphosate.

Digital Media Links

LOGO: Download Taming Your Flame logo

VIDEO: Taming Your Flame Courses Introduction Video

BIOS: Biographies of Dr. Louis Scoma and Dr. Eric Gerken

HEADSHOT: Dr. Louis Scoma headshot

Photo credit: M&M Multimedia

HEADSHOT: Dr. Eric Gerken headshot

Photo credit: M&M Multimedia

About Tame Your Flame

Tame the Flame, LLC, headquartered in Cape Coral, Florida is a producer of educational personal healthcare courses, delivered primarily online. Founded in 2019 by Dr. Louis Scoma and Dr. Eric Gerken, the Taming Your Flame library of online classes helps people learn about, prevent and manage chronic inflammation, the leading cause of all chronic diseases. Learn more at tamingyourflame.com. Contact Dr. Scoma at (239) 464-8304 or info@tamingyourflame.com.

Share article on social media or email:

Rapper Travis Scott Makes it a Birthday to Remember for Local Fan During Childhood Cancer Awareness Month


During National Childhood Cancer Awareness Month, rapper Travis Scott helped one fan celebrate his birthday which sparked the fan’s uncle to create a GoFundMe page to support treatment costs.

Jonah DeToro, who marked his 20th birthday at the Children’s Hospital of Wisconsin, tweeted his favorite musician while enjoying a birthday treat of the recently released “Travis Scott Meal” from McDonald’s. DeToro tweeted, “No better way to fight cancer than having a #TravisScottmeal on my birthday,” and Scott shared the message far and wide, earning hundreds of thousands of retweets and well wishes.

https://twitter.com/trvisXX/status/1303568488573710337?s=20

Scott’s message spurred the creation of the GoFundMe site to help family pay for the treatment of DeToro’s brain and spinal tumors.

September is designated Childhood Cancer Awareness Month to bring greater attention to pediatric cancer and to help treat and defeat cancer. Every day, 43 kids in the United States are diagnosed with cancer yet survival rates continue to grow as new treatments are developed.

“During this month dedicated to awareness and treatment, Jonah got the ultimate birthday surprise from his favorite rapper,” said DeToro’s uncle, Adam Greenspan, an integral part of “Team Jonah” and has helped with fundraising for hospital costs. “We are so grateful for the outpouring of support from friends and strangers alike and want to continue to shine a light on the need for research, treatment and care for kids facing challenging circumstances at a young age.”

DeToro previously overcame a brain tumor on his pituitary stalk, and is now preparing to undergo a four- to six-week hospital stay for additional chemotherapy and a bone marrow transplant.

“I want to give another shout out to Travis for making a difference and send some love to everyone who is going through this,” DeToro said. “There is nothing easy about a cancer diagnosis, but it definitely helps to have family and friends – not to mention Travis Scott fans from all over the world – who contribute in so many ways.”

For more information or to contribute to DeToro’s GoFundMe, please visit https://www.gofundme.com/f/jonah-detoro.

Share article on social media or email:



ActiGraph Expands Executive Leadership Team with Three Key Hires


These individuals bring a wealth of talent, expertise, and enthusiasm for their disciplines that will be integral in driving ActiGraph’s continued growth as a global digital medicine technology solutions provider.

ActiGraph, a leading global provider of medical-grade wearable physical activity and sleep monitoring solutions for pharmaceutical and academic research, announced the hiring of three key members of its executive leadership team. Joining ActiGraph are Kuno van der Post, Chief Commercial Officer, Lynda Barr, Chief Financial Officer, and Scott Ginnetti, Vice President of Human Resources and Culture.

“We are thrilled to welcome Kuno, Lynda, and Scott to ActiGraph,” said Jeremy Wyatt, Chief Executive Officer. “Following our investment by ArchiMed earlier this year, expansion of our executive leadership team was a critical first step in executing our long-term growth strategy. These individuals bring a wealth of talent, expertise, and enthusiasm for their disciplines that will be integral in driving ActiGraph’s continued growth as a global digital medicine technology solutions provider.”

Kuno van der Post, Chief Commercial Officer

Kuno van der Post is ActiGraph’s global head of sales and marketing, responsible for the development and implementation of the company’s commercial strategy. He has more than 21 years of experience in software and equipment sales within the life sciences industry at Europa Scientific, Labvantage, Waters, Medidata and commercial leadership positions at Oracle and OmniComm Systems covering Europe, the Far East, North America and Latin America. He is well known in the industry and has a proven record of developing and implementing successful sales and marketing teams and strategies.

Lynda Barr, Chief Financial Officer

Lynda Barr has spent the last 20 years of her career working in private equity owned companies, including Chief Financial Officer in manufacturing, retail, and service sectors and serving as Financial Director at Riverside Company, a global private equity firm investing in lower middle market companies. Most recently, Lynda was Chief Financial Officer for Standard Furniture (Bay Minette, AL).

Scott Ginnetti, Vice President of Human Resources and Culture

Scott Ginnetti will play a critical role in accelerating ActiGraph’s continued transformation journey. He brings more than 16 years of experience pioneering people strategies and building diverse and inclusive organizations. Ginnetti most recently served as the Vice President of Transformation & People at Intelligent Retinal Imaging System (IRIS), a high-growth healthcare technology company, where he helped evolve the company’s people strategy to transform IRIS into a market leader in retinal imaging. He has also held progressive strategic leadership roles at Signature HealthCare (Louisville, KY), Baptist Health Care (Pensacola, FL), and The Home Depot (Atlanta, GA). Scott is best known for his people-centered approach towards transforming culture and improving business performance.

About ActiGraph – ActiGraph is a leading provider of medical-grade physical activity and sleep monitoring solutions for the global scientific community. The company’s FDA-cleared wearable activity monitors and robust data management and analytics platform have been used extensively to quantify human movement in academic and population health research for two decades. More recently, ActiGraph technology solutions have been widely adopted by pharmaceutical and life sciences organizations seeking to capture and monitor real-world physical activity, mobility, and sleep behavior for participants enrolled in clinical trials. Learn more at actigraphcorp.com

Share article on social media or email:

BioFit Introduces JAMES™ Cart to Meet Demand in Janitorial, Industrial and Sanitation Markets


BioFit JAMES tools toolbox steel construction 400 pound capacity janitorial assembly manufacturing engineering sanitation cart

The BioFit JAMES Cart meets customer demand for tough, flexible and nimble material and tool conveyance in a variety of work environments.

The JAMES cart meets demand for a better way to move materials and keep frequently used tools close at hand on the factory floor, provide a compact means to maneuver around the office with cleaning supplies, and even serve as a sign-in and temperature-check center at employee access control points.

BioFit Engineered Products, a global leader in the design and fabrication of technical ergonomic seating and commercial furnishing solutions, announced today the launch of a multipurpose cart designed for janitorial, assembly, manufacturing, engineering and sanitation applications. Created to transport tools, equipment and supplies in multishift operations or even serve as a self-contained employee COVID-19 check-in center, the JAMES™ mobile platform was specially developed to aid users in today’s workspaces.

The BioFit JAMES cart is the newest addition to the company’s multipurpose cart and book truck line. It’s tested and proven to deliver versatility, mobility and long-term durability based on evaluations in real-world industrial, technology and training settings. Highlights include two 4” deep trays to provide ample space for materials and equipment, and to keep gear secured during transport, while twin side-panel steel pegboards hold tools, supplies and more. All-steel welded construction and heavy-duty casters combine to withstand loads of up to 400 lbs., and a powder-coat finish in a selection of colors stands up to years of daily use and enables fast and efficient cleaning and disinfecting. The JAMES cart’s maneuverability and compact profile make it ideal for confined areas, and its 13-year warranty helps businesses of any size realize positive return on investment.

“Our primary objective with any product we develop is always to help workers perform better, and the JAMES cart does just that,” explained Ed Metzger, President of BioFit. He continued: “It just made sense at this time to literally roll out a solution to meet increasing demand for a better way to move materials and keep frequently used tools close at hand on the factory floor, provide a compact means to maneuver around the office with cleaning supplies, and even function as the sign-in and temperature-check center of the now ubiquitous employee access control stations instituted as a result of the pandemic. The JAMES cart is at your service in so many ways.”

Headquartered in Bowling Green, Ohio, BioFit Engineered Products is an industry-leading manufacturer of LEED® compliant ergonomic seating, GREENGUARD Gold certified cafeteria and mobile folding tables, book trucks, carts, and specialty products for industrial, office, education, high-tech, healthcare, laboratory and custom applications. To learn more about BioFit, visit https://www.biofit.com, call 800-597-0246 or email biofit@biofit.com.

Share article on social media or email: